{"prompt": "['Novartis', 'Confidential', 'Page 54', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', \"visits. Continuous remote monitoring of each site's data may be performed by a centralized\", 'Novartis CRA organization. Additionally, a central analytics organization may analyze data &', 'identify risks & trends for site operational parameters, and provide reports to Novartis clinical', 'teams to assist with trial oversight.', 'The Investigator must maintain source documents for each subject in the study, consisting of', 'case and visit notes (hospital or clinic medical records) containing demographic and medical', 'information, laboratory data, electrocardiograms, and the results of any other tests or', 'assessments. All information on CRFs must be traceable to these source documents in the', \"subject's file. The Investigator must also keep the original informed consent form signed by the\", 'subject (a signed copy is given to the subject).', 'The Investigator must give the monitor access to all relevant source documents to confirm their', 'consistency with the data capture and/or data entry. Novartis monitoring standards require full', 'verification for the presence of informed consent, adherence to the inclusion/exclusion criteria,', 'documentation of SAEs, and of data that will be used for all primary variables. Additional', 'checks of the consistency of the source data with the CRFs are performed according to the', 'study-specific monitoring plan. No information in source documents about the identity of the', 'subjects will be disclosed.', '12', 'Data analysis and statistical methods', 'The primary efficacy and safety analyses will be conducted at the time the trial ends. All data', 'captured in the study up to the end of study will be analyzed and reported.', 'Any data analysis carried out independently by the Investigator should be submitted to Novartis', 'before publication or presentation.', '12.1', 'Analysis sets', 'The Full Analysis Set (FAS) will be comprised of all randomized patients who meet both of', 'the following criteria:', 'Received at least one dose of study treatment', 'Have a baseline NPS score > 4 as measured by the central reader.', 'According to the intent to treat principle, subjects will be analyzed according to the treatment', 'they have been assigned to at the randomization. However, if patients received study', 'treatment without being randomized into the study they will be excluded from the FAS.', 'The Safety Analysis Set (SAF) includes all subjects who received at least one dose of study', 'treatment. Subjects will be analyzed according to the study treatment received, where treatment', 'received is defined as the randomized/assigned treatment if the patient took at least one dose of', 'that treatment or the first treatment received if the randomized/assigned treatment was never', 'received.', 'The analysis of the primary objectives will be performed on the FAS. The FAS will be used for', 'the analysis of all other efficacy variables. The SAF will be used in the analysis of all safety', 'variables.']['Novartis', 'Confidential', 'Page 55', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', '12.2', 'Subject demographics and other baseline characteristics', 'Demographic and other baseline data including disease characteristics will be listed and', 'summarized descriptively by treatment group for the FAS.', 'Categorical data will be presented as frequencies and percentages. For continuous data, mean,', 'standard deviation (SD), median, minimum, and maximum will be presented. For selected', 'parameters, 25th and 75th percentiles will also be presented.', 'Relevant medical histories and current medical conditions at baseline will be summarized by', 'system organ class and preferred term, by treatment group.', '12.3', 'Treatments', 'The Safety Analysis Set will in general be used for the analyses of treatments. Categorical data', 'will be summarized as frequencies and percentages. For continuous data, mean, standard', 'deviation, median, 25th and 75th percentiles, minimum, and maximum will be presented.', 'The duration of exposure (expressed in weeks), the dose intensity (computed as the ratio of', 'actual cumulative dose received and actual duration of exposure) and the relative dose intensity', '(computed as the ratio of dose intensity and planned dose intensity) will be summarized by', 'means of descriptive statistics.', 'The number of patients with dose adjustments (reductions, interruption, or permanent', 'discontinuation) and the corresponding reasons will be summarized for the study treatment.', 'Compliance with study medication over the course of the entire study will be summarized as', 'the percentage of days with study medication intake during the period from first intake to last', 'intake.', 'All fevipiprant dosing data will be listed.', 'Concomitant medications and significant non-drug therapies prior to and after the start of the', 'study treatment will be listed and summarized according to the Anatomical Therapeutic', 'Chemical (ATC) classification system in the Safety Analysis Set.', 'Concomitant nasal polyp related medications will be summarized by pre-defined category.', '12.4', 'Analysis of the primary endpoint(s)', 'The primary aim of the study is to evaluate a change in nasal polyp size with fevipiprant (150', 'mg or 450 mg once daily, separately) as compared to placebo. This will be evaluated by using', 'the nasal polyp score (NPS) which is assessed by nasal endoscopy and determined by central', 'reading. The total NPS is recorded as the sum of the right and left nostril scores with a range of', '0 to 8 A decrease in the NPS is considered a favorable outcome.', 'The analysis of the primary endpoint will be conducted according to the intention to treat', 'principle using FAS population.']\n\n###\n\n", "completion": "END"}